Concurrent Investment Advisors LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,203 shares of the company's stock, valued at approximately $361,000.
Several other institutional investors also recently bought and sold shares of the business. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $38,000. CIBC Private Wealth Group LLC lifted its position in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after acquiring an additional 152 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,000. McIlrath & Eck LLC lifted its position in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $93,000. 99.95% of the stock is owned by institutional investors and hedge funds.
Prestige Consumer Healthcare Price Performance
PBH stock opened at $76.33 on Friday. The business has a fifty day moving average of $83.76 and a two-hundred day moving average of $82.36. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of 17.79, a price-to-earnings-growth ratio of 2.33 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 52-week low of $64.94 and a 52-week high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.02 earnings per share. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently commented on PBH shares. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $93.33.
View Our Latest Research Report on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.